Karyopharm Therapeutics (NASDAQ: KPTI) is one of 285 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Karyopharm Therapeutics to related businesses based on the strength of its risk, valuation, profitability, earnings, analyst recommendations, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings for Karyopharm Therapeutics and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Karyopharm Therapeutics 0 0 7 0 3.00
Karyopharm Therapeutics Competitors 845 3193 11580 230 2.71

Karyopharm Therapeutics currently has a consensus target price of $17.43, suggesting a potential upside of 63.50%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.44%. Given Karyopharm Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Karyopharm Therapeutics is more favorable than its rivals.

Risk and Volatility

Karyopharm Therapeutics has a beta of 4.09, suggesting that its share price is 309% more volatile than the S&P 500. Comparatively, Karyopharm Therapeutics’ rivals have a beta of 1.80, suggesting that their average share price is 80% more volatile than the S&P 500.

Earnings and Valuation

This table compares Karyopharm Therapeutics and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Karyopharm Therapeutics $150,000.00 -$109.57 million -4.01
Karyopharm Therapeutics Competitors $284.30 million $34.29 million 129.99

Karyopharm Therapeutics’ rivals have higher revenue and earnings than Karyopharm Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.


This table compares Karyopharm Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Karyopharm Therapeutics -67,267.47% -76.83% -68.22%
Karyopharm Therapeutics Competitors -5,355.33% -433.53% -38.99%

Insider and Institutional Ownership

60.9% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, 50.3% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 14.7% of Karyopharm Therapeutics shares are owned by company insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. The Company’s lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. It is also engaged in the clinical development of selinexor in various solid tumor indications. Oral selinexor is being evaluated in multiple later-phase clinical trials in patients with relapsed and/or refractory hematological and solid tumor malignancies. Its lead drug candidate, oral selinexor (KPT-330), as well as verdinexor (KPT-335), KPT-8602 and KPT-9274 are in clinical development.

Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.